全文获取类型
收费全文 | 29570篇 |
免费 | 2866篇 |
国内免费 | 134篇 |
专业分类
耳鼻咽喉 | 258篇 |
儿科学 | 1014篇 |
妇产科学 | 677篇 |
基础医学 | 4244篇 |
口腔科学 | 662篇 |
临床医学 | 3783篇 |
内科学 | 6543篇 |
皮肤病学 | 729篇 |
神经病学 | 2988篇 |
特种医学 | 753篇 |
外国民族医学 | 4篇 |
外科学 | 3393篇 |
综合类 | 229篇 |
一般理论 | 5篇 |
预防医学 | 2548篇 |
眼科学 | 375篇 |
药学 | 1848篇 |
中国医学 | 26篇 |
肿瘤学 | 2491篇 |
出版年
2023年 | 263篇 |
2022年 | 428篇 |
2021年 | 843篇 |
2020年 | 649篇 |
2019年 | 971篇 |
2018年 | 1106篇 |
2017年 | 871篇 |
2016年 | 939篇 |
2015年 | 982篇 |
2014年 | 1195篇 |
2013年 | 1614篇 |
2012年 | 2049篇 |
2011年 | 1991篇 |
2010年 | 1284篇 |
2009年 | 1138篇 |
2008年 | 1719篇 |
2007年 | 1742篇 |
2006年 | 1633篇 |
2005年 | 1538篇 |
2004年 | 1470篇 |
2003年 | 1318篇 |
2002年 | 1244篇 |
2001年 | 459篇 |
2000年 | 433篇 |
1999年 | 418篇 |
1998年 | 315篇 |
1997年 | 226篇 |
1996年 | 192篇 |
1995年 | 192篇 |
1994年 | 160篇 |
1993年 | 150篇 |
1992年 | 216篇 |
1991年 | 207篇 |
1990年 | 206篇 |
1989年 | 202篇 |
1988年 | 165篇 |
1987年 | 153篇 |
1986年 | 162篇 |
1985年 | 145篇 |
1984年 | 144篇 |
1983年 | 130篇 |
1982年 | 103篇 |
1981年 | 98篇 |
1980年 | 69篇 |
1979年 | 101篇 |
1978年 | 75篇 |
1977年 | 76篇 |
1976年 | 80篇 |
1975年 | 64篇 |
1973年 | 62篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
901.
Bartzela T Katsaros C Rønning E Rizell S Semb G Bronkhorst E Halazonetis D Kuijpers-Jagtman AM 《Clinical oral investigations》2012,16(4):1313-1324
In this longitudinal study, the craniofacial morphology and evaluated soft tissue profile changes, at 6 and 12 years of age in patients with complete bilateral cleft lip and palate (CBCLP) were compared. Lateral cephalograms from 148 patients with CBCLP, treated consecutively at three European cleft centers, Gothenburg (n (A) = 37), Nijmegen (n (B) = 26), and Oslo (n (C) = 85), were evaluated. Eighteen hard tissue and ten soft tissue landmarks were digitized. Paired t test, Pearson's correlation coefficients, and multiple regression models were applied for statistical analysis. ANOVA and Tukey-B, as a post hoc test, were used to evaluate the increments and compare centers. Hard and soft tissue data were superimposed using the generalized Procrustes analysis. For Nijmegen, the increments of the variables SNA, ANB, SN-NL, SN-ML, NL-ML, Snss, and Snpg were significantly different than the two other centers (p = 0.041 to <0.001). SNPg increments were significantly different between Nijmegen and Oslo (p = 0.002). The three cleft centers followed different treatment protocols, but the main differences in craniofacial morphology until 12 years of age were the growth pattern and the maxillary and upper incisor variables. Follow-up of these patients until facial growth has ceased, which may elucidate components for improving treatment outcome. 相似文献
902.
903.
Ratsimbasoa A Ravony H Vonimpaisomihanta JA Raherinjafy R Jahevitra M Rapelanoro R Rakotomanga Jde D Malvy D Millet P Ménard D 《The American journal of tropical medicine and hygiene》2012,86(2):203-210
Home management of malaria is recommended for prompt, effective antimalarial treatment in children less than five years of age. Compliance, safety, and effectiveness of the new fixed-dose artesunate-amodiaquine regimen used to treat suspected malaria were assessed in febrile children enrolled in a 24-month cohort study in two settings in Madagascar. Children with fever were asked to visit community health workers. Presumptive antimalarial treatment was given and further visits were scheduled for follow-up. The primary endpoint was the risk of clinical/parasitologic treatment failure. Secondary outcomes included fever/parasite clearance, change in hemoglobin levels, and frequency of adverse events. The global clinical cure rate was 98.4% by day 28 and 97.9% by day 42. Reported compliance was 83.4%. No severe adverse effects were observed. This study provides comprehensive data concerning the clinical cure rate obtained with artesunate-amodiaquine and evidence supporting the scaling up of home management of malaria. 相似文献
904.
905.
906.
907.
Lioure B Béné MC Pigneux A Huynh A Chevallier P Fegueux N Blaise D Witz B Delain M Cornillon J Luquet I Blanchet O Cornillet-Lefebvre P Carré M Hunault M Larosa F Lamy T Randriamalala E Ojeda-Uribe M Berthou C Fornecker L Harousseau JL Bouscary D Ifrah N Cahn JY;GOELAMS 《Blood》2012,119(12):2943-2948
The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger patients, while the older ones received a consolidation course, followed by peripheral blood allo-HSCT using RIC. The incidence of grade II-IV acute GVHD, was 51.9% (95% confidence interval [CI]: 42.1-61.8) and 11.3% (1.6-21.2) after myeloablative or RIC, respectively (P < .0001) and that of chronic GVHD 45.8% (95% CI: 34.8-56.7) and 41.7% (24.7-58.6; NS). Cumulative incidence of nonrelapse mortality at 108 months was 15.8% (95% CI: 9.8-23.2) for myeloablative, and 6.5% (0.2-16.2) for RIC (NS). CI of relapse at 108 months was 21.7% (95% CI: 13.9-28.6) and 28.6% (16.5-43.4; NS). Overall survival at 108 months was 63.4% (95% CI: 54.6-72.2) and 65.8% (52.2-72.2), respectively, after myeloablative or RIC (NS). RIC peripheral blood stem cell allo-HSCT is prospectively feasible for patients between the ages of 51 and 60 years without excess of relapse or nonrelapse mortality, and compares favorably with myeloablative marrow allo-HSCT proposed to younger patients. 相似文献
908.
Terrier B Krastinova E Marie I Launay D Lacraz A Belenotti P de Saint-Martin L Quemeneur T Huart A Bonnet F Le Guenno G Kahn JE Hinschberger O Rullier P Diot E Lazaro E Bridoux F Zénone T Carrat F Hermine O Léger JM Mariette X Senet P Plaisier E Cacoub P 《Blood》2012,119(25):5996-6004
Data on the clinical spectrum and therapeutic management of noninfectious mixed cryoglobulinemia vasculitis (CryoVas) in the era of hepatitis C virus screening are lacking. We analyzed data from 242 patients with noninfectious mixed CryoVas included in the French multicenter CryoVas survey. Baseline manifestations were purpura (75%), peripheral neuropathy (52%), arthralgia or arthritis (44%), glomerulonephritis (35%), cutaneous ulcers (16%), and cutaneous necrosis (14%). A connective tissue disease was diagnosed in 30% and B-cell non-Hodgkin lymphoma in 22%, whereas the CryoVas was considered to be essential in 48%. With the use of Cox-marginal structural models, rituximab plus corticosteroids showed the greater therapeutic efficacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve complete clinical, renal, and immunologic responses and a prednisone dosage < 10 mg/d at 6 months. However, this regimen was also associated with severe infections, particularly when high doses of corticosteroids were used, whereas death rates did not differ between the therapeutic regimens. The role of each of these strategies remains to be defined in well-designed randomized controlled trials. 相似文献
909.
Cairns RA Iqbal J Lemonnier F Kucuk C de Leval L Jais JP Parrens M Martin A Xerri L Brousset P Chan LC Chan WC Gaulard P Mak TW 《Blood》2012,119(8):1901-1903
Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset of acute myelogenous leukemias but have not been detected in other tumor types. The mutations occur at specific arginine residues and result in the acquisition of a novel enzymatic activity that converts 2-oxoglutarate to D-2-hydroxyglutarate. This study reports IDH1 and IDH2 genotyping results from a set of lymphomas, which included a large set of peripheral T-cell lymphomas. IDH2 mutations were identified in approximately 20% of angioimmunoblastic T-cell lymphomas (AITLs), but not in other peripheral T-cell lymphoma entities. These results were confirmed in an independent set of AITL patients, where the IDH2 mutation rate was approximately 45%. This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role. 相似文献
910.
Wolf D von Lilienfeld-Toal M Wolf AM Schleuning M von Bergwelt-Baildon M Held SA Brossart P 《Blood》2012,119(1):16-25
Acute and chronic graft-versus-host disease (GVHD) are potentially lethal complications after stem cell transplantation (SCT). Steroids are the appropriate first-line treatment for both. However, if patients do not adequately benefit from steroid therapy, mortality is high and standardized treatment algorithms are lacking. This is mainly because of limited data from prospective, randomized clinical trials. In addition, most of the available treatment options only induce clinical benefits in a limited proportion of patients. Thus, there is an urgent clinical need to develop more potent immunosuppressive treatment strategies for patients suffering from acute or chronic steroid-refractory GVHD while maintaining the graft versus tumor effect to avoid a potential rise in relapse-related mortality. The increasing knowledge about host- as well as donor-derived variables favoring GVHD development and the increasing armamentarium of immune-modulatory agents entering preclinical and clinical research will probably allow more effective treatment of GVHD in the future. This review describes novel developments in the treatment of steroid-refractory GVHD, with a special focus on the rationale behind promising pharmacologic compounds or up-coming cellular therapies. 相似文献